Navigation Links
Haemonetics Reports 8% Revenue Growth for Second Quarter of Fiscal 2012, Adjusted Earnings Per Share of $0.72 and Updates Previously Provided Full Year Earnings Guidance
Date:10/31/2011

0; 913Other current liabilities

107,726107,758Total current liabilities

110,806108,671Long-term debt

3,3323,966Other long-term liabilities

31,30734,491Stockholders' equity

678,277686,136   Total liabilities & stockholders' equity

$823,722$833,264Free Cash Flow ReconciliationThree Months Ended10/1/201110/2/2010GAAP cash flow from operations

$25,408$30,730Capital expenditures

(12,042)(8,864)Proceeds from sale of property, plant and equipment

111151Net investment in property, plant and equipment

(11,931)(8,713)Free cash flow after transformation and deal costs

13,47722,017Transformation and deal costs

2,8072,3252,8072,325Free cash flow before transformation and deal costs

$16,284$24,342Six Months Ended10/1/201110/2/2010GAAP cash flow from operations

$52,539$44,286Capital expenditures

(23,843)(24,088)Proceeds from sale of property, plant and equipment

130262Net investment in property, plant and equipment

(23,713)(23,826)Free cash flow

28,82620,460Transformation and deal costs

4,5856,383Global Med employment contracts

-2,1224,5858,505Free cash flow before transformation and deal costs

$33,411$28,965Haemonetics Corporation Financial SummaryReconciliation of Non-GAAP MeasuresHaemonetics has presented supplemental non-GAAP financial measures as part of this earnings release.  A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure.  The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures.  There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.These measures are used by management to monitor the financial performance of
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Haemonetics Sets Date for Second Quarter Fiscal Year 2012 Earnings Release: October 31, 2011
2. Haemonetics Sets Date for Fourth Quarter Fiscal Year 2011 Earnings Release: May 2, 2011
3. Haemonetics to Present at J.P. Morgan Healthcare Conference
4. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
5. Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
6. ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
7. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
8. Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
9. Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2011
10. ERT Reports Third Quarter 2011 Operating Results
11. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... sodium injection) were also ... within 90 days-, BRIDGEWATER, N.J., Dec 10 ... total hospital,direct medical costs associated with VTE treatment are ... the use of low-molecular weight heparin,(LMWH) vs. unfractionated heparin ...
... 10 Alfacell Corporation,(Nasdaq: ACEL ) today reported ... The company recorded a net loss of approximately ... for the fiscal quarter ended Oct. 31,compared to a ... and diluted,common share, for the first quarter of fiscal ...
Cached Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Alfacell Reports Financial Results for First Quarter of Fiscal 2008 2Alfacell Reports Financial Results for First Quarter of Fiscal 2008 3Alfacell Reports Financial Results for First Quarter of Fiscal 2008 4Alfacell Reports Financial Results for First Quarter of Fiscal 2008 5
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... has released a new blog post presenting the basic features ... Purchasing an accidental death and dismemberment rider for a car ... provides benefits if the insured dies in an accident. Accidental ... life insurance. , AD&D is not expensive and can ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... N.J. (September 9, 2010) Researchers from the John Theurer ... role in a study that led to the Food & ... treatment for metastatic melanoma. The FDA based its decision largely ... New England Journal of Medicine on August 19, ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. 9 ... goals for the amount of fruit and vegetables people should ... not even close to reaching those thresholds, health officials said ... Disease Control and Prevention, in 2009, 67.5 percent of adults ...
... By Kathleen Doheny HealthDay Reporter , THURSDAY, Sept. ... obesity throughout your life: Doing so may improve your chances of ... who are obese and diagnosed with colon cancer appear to face ... are at a healthy weight or merely overweight, a new study ...
... (NEEM) will open tomorrow in Riga, Latvia with prostate, ... the two-day meeting. "The discussion will focus on ... will present updates on a variety of subjects such ... results in radical prostatectomy, treatment options in high-risk non ...
... This release is available in French . ... published in The Journal of Sexual Medicine has ... sympathy to women,s chronic vulvovaginal pain may trigger more pain, ... Women who took part in the study, conducted by the ...
... News media and others interested in the chemical sciences ... of American Chemical Society (ACS) Webinars, focusing on how ... funding programs. Scheduled for Thursday, Sept. 16, from ... will feature Josephine Yuen, Ph.D., NSF Program Director, speaking ...
Cached Medicine News:Health News:Promising treatment for metastatic melanoma 'fast tracked' by FDA 2Health News:Promising treatment for metastatic melanoma 'fast tracked' by FDA 3Health News:Most Americans Still Not Eating Enough Fruits, Veggies 2Health News:Most Americans Still Not Eating Enough Fruits, Veggies 3Health News:Obesity May Up Death Risk in Older Women With Colon Cancer 2Health News:Obesity May Up Death Risk in Older Women With Colon Cancer 3Health News:Romantic partner may play role in reducing vulvovaginal pain 2Health News:American Chemical Society Webinar focuses on NSF's small business funding programs 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: